Oncology (Williston Park). 2015 Jan;29(1):23-30, 37.
Bisphosphonates have played an important role in the treatment of breast cancer, mainly in patients with bone metastasis, by reducing the risk of fracture, spinal cord compression, and hypercalcemia. Both oral and intravenous products are available and have strong supporting clinical evidence. Zoledronic acid, the most frequently used intravenous agent, has traditionally been given on a monthly dosing schedule. A novel every-12-weeks maintenance dosing schedule shows clinical equivalence and promises to improve safety, affordability, and quality of care. The Early Breast Cancer Trialists' Collaborative Group has recently helped clarify the controversial benefit of bisphosphonates in the adjuvant setting. Based on their meta-analysis, we now have strong evidence supporting the use of adjuvant bisphosphonates to help prevent the development of bone metastasis in postmenopausal breast cancer patients, which leads to a significant improvement in breast cancer-specific survival. We eagerly await the full publication of this practice-changing study, which continues the incremental advance of the treatment of patients with breast cancer.
双膦酸盐在乳腺癌的治疗中发挥了重要作用，主要用于治疗骨转移患者，可降低骨折、脊髓压迫和高钙血症的风险。既有口服制剂也有静脉制剂，且都有强有力的临床证据支持。唑来膦酸是最常用的静脉用药物，传统上采用每月给药方案。一种新的每 12 周维持剂量方案显示出临床等效性，并有望提高安全性、可负担性和护理质量。早期乳腺癌试验者协作组最近帮助澄清了辅助治疗中双膦酸盐的有争议的益处。基于他们的荟萃分析，我们现在有强有力的证据支持使用辅助性双膦酸盐来帮助预防绝经后乳腺癌患者发生骨转移，从而显著改善乳腺癌特异性生存。我们急切地等待这项改变实践的研究的全文发表，该研究继续推动乳腺癌患者治疗的逐步进展。
